Since carriers of Pi*MZ and Pi*SZ also exhibit a two‐ and three‐fold risk of fibrosis/cirrhosis, respectively, we advocate liver function tests once a year and VCTE‐LSM every five years, with decision rules as suggested in the recent Delphi consensus for Pi*ZZ carriers, in these patients [33, 59]. Here, SERPINA1 is linked to fibrosis.